Prosecution Insights
Last updated: November 20, 2026
Application No. 18/680,689

SYNTHESIS OF A BIS-MESYLATE SALT OF 4-AMINO-N-(1-((3-CHLORO-2-FLUOROPHENYL)AMINO)-6-METHYLISOQUINOLIN-5-YL)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE AND INTERMEDIATES THERETO

Final Rejection §102§DOUBLEPATENT
Filed
May 31, 2024
Priority
Jun 30, 2021 — CN PCT/CN2021/103873 +1 more
Examiner
MOORE, SUSANNA
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Hoffmann-La Roche Inc.
OA Round
2 (Final)
68%
Grant Probability
Favorable
3-4
OA Rounds
5m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 68% — above average
68%
Career Allowance Rate
864 granted / 1271 resolved
+8.0% vs TC avg
Strong +32% interview lift
Without
With
+31.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
76 currently pending
Career history
1356
Total Applications
across all art units

Statute-Specific Performance

§101
1.5%
-38.5% vs TC avg
§103
17.5%
-22.5% vs TC avg
§102
16.4%
-23.6% vs TC avg
§112
40.3%
+0.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1271 resolved cases

Office Action

§102 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . This is a Final Office Action. Claims 1, 3, 6, 7 and 9 are pending and claims 1, 6, 7 and 9 are under examination. Newly submitted claim 3 directed to an invention that is independent or distinct from the invention originally claimed for the following reasons: claim 3 has been amended from compound 2 to a different invention, compound 26. Since Applicant has received an action on the merits for the originally presented invention, this invention has been constructively elected by original presentation for prosecution on the merits. Accordingly, claim 3 is withdrawn from consideration as being directed to a non-elected invention. See 37 CFR 1.142(b) and MPEP § 821.03. To preserve a right to petition, the reply to this action must distinctly and specifically point out supposed errors in the restriction requirement. Otherwise, the election shall be treated as a final election without traverse. Traversal must be timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are subsequently added, applicant must indicate which of the subsequently added claims are readable upon the elected invention. Should Applicant traverse on the ground that the inventions are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103 or pre-AIA 35 U.S.C. 103(a) of the other invention. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Claim Rejections - 35 USC § 102 The rejection of claim(s) 3 under 35 U.S.C. 102(a)(1) and 102(a)(2) as being anticipated by Son et al. (US 8999973) is withdrawn based on the amendments. Claim Rejections - 35 USC § 102/103 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim(s) 1, 6 and 7 is/are rejected under 35 U.S.C. 102(a)(1) and 102(a)(2) as anticipated by or, in the alternative, under 35 U.S.C. 103 as obvious over Bae et al. (US 9156852) in view of Berge et al. (Journal of Pharmaceutical Sciences, 1977, 66(1), 1-19). The present application claims a compound of formula 1b: PNG media_image1.png 123 324 media_image1.png Greyscale as a product by process claim, wherein the process recrystallizes the final compound to a purity of >99A% by HPLC. The reference teaches the following species: PNG media_image2.png 124 713 media_image2.png Greyscale , see columns 97-98. The reference further teaches methane sulfonic acid as a preferred salt, see column 4, lines 53-55, from a small list of salts. Assuming, arguendo, claim 1 is not anticipatory, then claim 1 is rendered obvious in view of Berge, which teaches methane sulfonic acid as an FDA approved salt, see Table 2. Purer forms of known products may be patentable, but the mere purity of a product, by itself, does not render the product nonobvious, see MPEP 2144.04. However, it would have been prima facie obvious to one having ordinary skill in the art at the time the invention was made to purify the known materials to a greater degree of purity, one skilled in the art would be motivated because, according to MPEP 2144.04, purifying a known product having the same utility is prima facie obvious. Thus, claims 1, 6 and 7 are anticipated by or, in the alternative, under 35 U.S.C. 103 as obvious over Bae et al. in view of Berge et al. Applicant traverses by stating, “Regarding Bae on its own: Bae teaches a large genus of thieno[3,2-d]pyrimidine compounds, of which 116 are specifically exemplified. The possibility of choosing salts from a list - even a "small list" - still presents one of ordinary skill in the art with a formidable array of molecules from which to have deduced Applicant's compound lb.” This is not persuasive. A genus may be so small that, when considered in light of the totality of the circumstances, it would anticipate the claimed species or subgenus. For example, it has been held that a prior art genus containing only 20 compounds and a limited number of variations in the generic chemical formula inherently anticipated a claimed species within the genus because "one skilled in [the] art would... envisage each member" of the genus. In re Petering, 301 F.2d 676, 681, 133 USPQ 275, 280 (CCPA 1962), see MPEP 2144.08. Applicant further states, “Regarding Bae in conjunction with Berge, the argument is no different. Of course, the Examiner can still deploy hindsight to project a selection of methyl sulfonic acid as a plausible choice of counter-ion on to any of the molecules of Bae, but the analysis is the same: the rear-facing filter always makes the problem easier to define and to solve than does the forward-facing one at the time of Applicant's invention.” This is also not persuasive. It must be recognized that any judgment on obviousness is in a sense necessarily a reconstruction based upon hindsight reasoning. But so long as it takes into account only knowledge which was within the level of ordinary skill at the time the claimed invention was made, and does not include knowledge gleaned only from the applicant's disclosure, such a reconstruction is proper. See In re McLaughlin, 443 F.2d 1392, 170 USPQ 209 (CCPA 1971). Furthermore, Applicant's claim, as amended herein, recites a level of purity of lb that is made possible by the claimed process and the choice of methylsulfonate counter-ion (see, e.g., Applicant's specification at paragraph [0053]).” This is unpersuasive. Purer forms of known products may be patentable, but the mere purity of a product, by itself, does not render the product nonobvious., see MPEP 2144.04. Therefore, the rejection is maintained. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the claims at issue are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the reference application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The USPTO internet Web site contains terminal disclaimer forms which may be used. Please visit http://www.uspto.gov/forms/. The filing date of the application will determine what form should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to http://www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp. Claims 1, 6, 7 and 9 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-13 of U.S. Patent No. 11999749. Although the conflicting claims are not identical, they are not patentably distinct from each other because the present claims are drawn to compounds of formulas 1b, 2 and 1(THF). The claims in the ‘749 patent are drawn to a process of making said compounds. There is no patentable distinction between compounds and the process of making said compounds. Applicant disagrees with the Examiner’s statement that "[t]here is no patentable distinction between compounds and the process of making said compounds" but futher states, “Applicant is not averse to presenting a suitable terminal disclaimer at such time as the Examiner deems the claims to be allowable but for this issue of obviousness-type double patenting.” Therefore, the rejection is maintained. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUSANNA MOORE whose telephone number is (571)272-9046. The examiner can normally be reached Monday - Friday, 10:00 am to 7:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray can be reached on 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUSANNA MOORE/Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

May 31, 2024
Application Filed
May 12, 2026
Non-Final Rejection mailed — §102, §DOUBLEPATENT
Sep 14, 2026
Response Filed
Nov 02, 2026
Final Rejection mailed — §102, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799096
HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS
3y 8m to grant Granted Nov 17, 2026
Patent 12782368
CHEMILUMINESCENT ANDROSTENEDIONE CONJUGATES
7y 2m to grant Granted Nov 03, 2026
Patent 12767658
TETRACYCLIC PYRIMIDINONE COMPOUND, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF
4y 6m to grant Granted Oct 20, 2026
Patent 12760059
GLUCOCORTICOID RECEPTOR MODULATORS
3y 11m to grant Granted Oct 13, 2026
Patent 12753202
ANDROGEN RECEPTOR MODULATORS
4y 0m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
68%
Grant Probability
99%
With Interview (+31.6%)
2y 11m (~5m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1271 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month